URAC has joined more than 200 organizations in urging the Drug Enforcement Administration (DEA) to act swiftly in finalizing a Special Registration pathway for telemedicine prescribing of controlled substances. Without action, pandemic-era flexibilities will expire on December 31, 2025, putting millions of patients at risk of losing access to vital care.
“At URAC, we believe quality telehealth should be a treatment option available to patients wherever they live,” said Shawn Griffin, MD, URAC’s President and CEO. “This step is critical to supporting rural and underserved communities and maintaining continuity of care.”
URAC continues to support evidence-based telehealth through its rigorous accreditation process. A finalized Special Registration rule will help ensure patients can access safe, effective care without unnecessary disruption.
- Read the letter here
- Learn more about URAC’s telehealth accredidation program here
